Clinical trial
Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic…
NCT00002598 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00002598 |
|---|---|
| Title | Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia |
| Official title | A PHASE II STUDY OF MITOXANTRONE AND HIGH-DOSE ARA-C FOLLOWED BY INTENSIVE CONSOLIDATION WITH CYCLOPHOSPHAMIDE AND ETOPOSIDE FOR MYELOID BLAST CRISIS OF CHRONIC MYELOGENOUS LEUKEMIA (CML) |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug, Procedure, Radiation |
| Interventions | recombinant interferon alfa, sargramostim, cyclophosphamide, cytarabine, etoposide, methotrexate, mitoxantrone hydrochloride, bone marrow ablation with stem cell support, radiation therapy |
| Enrollment | 30 |
| Start date | Jun 1, 1994 |
| Primary completion | Jun 1, 2004 |
| Completion | Jun 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 25, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: